Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. have formed a strategic alliance to research and develop applications for AXIM's patented water-soluble cannabinoid technology. The collaboration centers on AXIM's U.S. Patent No. 11,542,226 B2, which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the agreement, AXIM assigned Medical Marijuana, Inc. a 50% right, title, and economic interest in the patent and all associated intellectual property. This includes rights to existing and future patents, licensing proceeds, and claims for past infringement. Medical Marijuana, Inc. paid $600,000 for this interest through a secured promissory note. Concurrently, the companies entered a consulting agreement where AXIM will provide research and development services focused on developing commercial applications for the patent technology. The consulting agreement has an initial one-year term with a monthly services fee of $62,500.
The technological breakthrough represented by this patent could have significant implications for cannabinoid-based treatments. The patented molecular engineering creates novel molecules that link cannabinoids to complementary compounds, improving delivery mechanisms and therapeutic effectiveness. These engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption and therapeutic delivery. According to AXIM's website at https://www.aximbiotech.com, this technology represents a major advancement in cannabinoid delivery systems.
Catalina Valencia, AXIM President, stated that the water solubility of CBD and other cannabinoids represents a significant development for improved administration and increased potency. "We believe that the Patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures," Valencia said. The enhanced efficacy with reduced toxicity could allow for lower therapeutic doses while avoiding toxic side effects associated with higher concentrations.
Dr. Timothy R. Scott, who returned as president of Medical Marijuana, Inc. in conjunction with the alliance, expressed confidence in the partnership. "We have tremendous confidence in the AXIM team's ability to provide R&D support for the development of commercialized uses of the Patent technology," Scott said. "The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA."
The alliance combines Medical Marijuana, Inc.'s market knowledge and distribution channels with AXIM's research capabilities. Medical Marijuana, Inc. manufactures and distributes hemp-derived CBD products worldwide through subsidiaries including HempMeds® and Kannaway®, which operates in multiple international markets as detailed on their corporate site at https://www.medicalmarijuanainc.com. This existing infrastructure could facilitate the commercialization of any products developed through the alliance.
The expanded treatment applications offered by this technology could address conditions where traditional oil-based cannabinoids have demonstrated limited bioavailability. The development of sublingual applications for anxiety and other indications represents a potentially significant advancement in cannabinoid therapeutics. The collaboration between these two companies aims to accelerate the development of practical applications for this patented technology, potentially creating new treatment options for patients while generating value for both organizations.
